Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis

Theodoros Karampitsakos; Ourania Papaioannou; Ilias Dimeas; Panagiota Tsiri; Vasilina Sotiropoulou; Ioannis Tomos; Ilias C Papanikolaou; Matthaios Katsaras; Paraskevi Kirgou; Zoe Daniil; Konstantinos I Gourgoulianis; Fotios Sampsonas; Effrosyni Manali; Spyridon Papiris; Demosthenes Bouros; Argyris Tzouvelekis

doi:10.1183/23120541.00082-2022

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis

ERJ Open Res. 2022 May 3;8(2):00082-2022. doi: 10.1183/23120541.00082-2022. eCollection 2022 Apr.

Authors

Theodoros Karampitsakos¹, Ourania Papaioannou¹, Ilias Dimeas², Panagiota Tsiri¹, Vasilina Sotiropoulou¹, Ioannis Tomos³, Ilias C Papanikolaou⁴, Matthaios Katsaras¹, Paraskevi Kirgou², Zoe Daniil², Konstantinos I Gourgoulianis², Fotios Sampsonas¹, Effrosyni Manali³, Spyridon Papiris³, Demosthenes Bouros⁵, Argyris Tzouvelekis¹

Affiliations

¹ Dept of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
² Dept of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
³ 2nd Pulmonary Medicine Dept, ATTIKON University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Respiratory Medicine Dept, Corfu General Hospital, Corfu, Greece.
⁵ First Academic Dept of Pneumonology, Hospital for Thoracic Diseases, SOTIRIA, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0.